{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T10:26:23Z","timestamp":1783506383079,"version":"3.55.0"},"reference-count":27,"publisher":"PAGEPress Publications","issue":"4","license":[{"start":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T00:00:00Z","timestamp":1762992000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Arch Ital Urol Androl"],"abstract":"<jats:p>Background: Androgen deprivation therapy (ADT) is a cornerstone treatment for advanced prostate cancer. While effective, traditional injectable luteinizing hormone-releasing hormone (LHRH) agonists are associated with an initial testosterone flare and potential cardiovascular risks. Relugolix is a novel, oral gonadotropin-releasing hormone (GnRH) antagonist developed to provide rapid suppression without a testosterone flare. This review synthesizes the latest evidence on the efficacy, safety, and clinical utility of relugolix. Methods: This non-systematic review was conducted via a search of PubMed and MEDLINE databases up to July 2025 using the terms \u201crelugolix\u201d AND \u201cADT\u201d OR \u201cAndrogen Deprivation Therapy\u201d AND \u201cProstate Cancer.\u201d Only original studies in English were included.Results: The phase III HERO trial established the superiority of relugolix over leuprolide, demonstrating higher rates of sustained castration (96.7% vs 88.8%) and a significantly faster onset of action. Relugolix also showed a 54% reduction in major cardiovascular adverse events. Furthermore, it exhibited equivalent efficacy to injectable degarelix when combined with radiotherapy, but with more robust testosterone recovery after treatment cessation (52% vs\u00a016%). Real-world data indicates high patient adherence to the oral regimen, and a cost-effectiveness analysis suggests it is a cost-effective option despite a higher drug cost. Conclusions: Relugolix represents a significant advancement in ADT, offering a potent, oral alternative with a rapid onset of action, a superior cardiovascular safety profile, and improved testosterone recovery. It provides clinicians with a valuable option for treating advanced prostate cancer, particularly in patients with cardiovascular comorbidities.<\/jats:p>","DOI":"10.4081\/aiua.2025.14277","type":"journal-article","created":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T14:13:23Z","timestamp":1763043203000},"source":"Crossref","is-referenced-by-count":2,"title":["Relugolix in treatment of prostate cancer: a review"],"prefix":"10.4081","volume":"97","author":[{"given":"Ioannis","family":"Kyriazis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Themistoklis","family":"Bellos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stamatios","family":"Katsimperis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Panagiotis","family":"Angelopoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Panagiotis","family":"Neofytoy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ioannis","family":"Varkarakis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Skolarikos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Athanasios","family":"Papatsoris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2549","published-online":{"date-parts":[[2025,11,13]]},"reference":[{"key":"202730","doi-asserted-by":"publisher","DOI":"10.1210\/endo-127-6-3052"},{"key":"202731","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(10)70223-0"},{"key":"202732","doi-asserted-by":"publisher","DOI":"10.1080\/14737167.2017.1375855"},{"key":"202733","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2004325"},{"key":"202734","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.2442"},{"key":"202735","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2020.03.001"},{"key":"202736","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2020.06.002"},{"key":"202737","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2024.1377103"},{"key":"202738","doi-asserted-by":"publisher","DOI":"10.1517\/13543784.10.4.709"},{"key":"202739","doi-asserted-by":"publisher","DOI":"10.1097\/UPJ.0000000000000445"},{"key":"202740","doi-asserted-by":"publisher","DOI":"10.1080\/14796694.2025.2480050"},{"key":"202741","doi-asserted-by":"publisher","DOI":"10.1093\/oncolo\/oyad036"},{"key":"202742","doi-asserted-by":"publisher","DOI":"10.1021\/jm200216q"},{"key":"202743","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2013.12.001"},{"key":"202744","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.35.2005"},{"key":"202745","doi-asserted-by":"publisher","DOI":"10.2165\/10484080-000000000-00000"},{"key":"202746","doi-asserted-by":"publisher","DOI":"10.1016\/j.urology.2007.12.070"},{"key":"202747","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2011.04.083"},{"key":"202748","unstructured":"19. Garnick MB, Campion M. Abarelix Depot, a GnRH antagonist, v LHRH superagonists in prostate cancer: differential effects on follicle-stimulating hormone. Abarelix Depot study group. Mol Urol 2000; 4:275-7."},{"key":"202749","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(01)06797-6"},{"key":"202750","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2009.11.029"},{"key":"202751","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdw372.18"},{"key":"202752","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2016.34.2_suppl.200"},{"key":"202753","doi-asserted-by":"publisher","DOI":"10.1016\/j.euo.2021.07.002"},{"key":"202754","doi-asserted-by":"publisher","DOI":"10.1016\/j.japh.2022.12.019"},{"key":"202755","doi-asserted-by":"publisher","DOI":"10.2217\/fon-2023-0748"},{"key":"202756","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaccao.2020.01.004"}],"container-title":["Archivio Italiano di Urologia e Andrologia"],"original-title":[],"link":[{"URL":"https:\/\/www.pagepressjournals.org\/aiua\/article\/download\/14277\/13542","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.pagepressjournals.org\/aiua\/article\/download\/14277\/13542","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,25]],"date-time":"2025-12-25T08:47:48Z","timestamp":1766652468000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.pagepressjournals.org\/aiua\/article\/view\/14277"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,13]]},"references-count":27,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2025,12,24]]}},"URL":"https:\/\/doi.org\/10.4081\/aiua.2025.14277","relation":{},"ISSN":["2282-4197","1124-3562"],"issn-type":[{"value":"2282-4197","type":"electronic"},{"value":"1124-3562","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11,13]]}}}